Alzamend Neuro eliminates Series A convertible preferred stock via Certificate of Elimination

Alzamend Neuro, Inc.

Filed Certificate of Elimination with Delaware Secretary of State on July 9, 2025 to cancel Series A Preferred Stock.
Certificate of Elimination removes all designations for Series A Preferred Stock from the company's charter.
No changes to fiscal year were made despite Item 5.03 title; only preferred stock elimination occurred.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Alzamend Neuro, Inc.: Eliminated Series A Preferred Stock Certificate of Designations from Certificate of Incorporation (effective 2025-07-09).

Change: charter amendment
Effective: 2025-07-09

Exact text from the filing

On July 9, 2025, Alzamend Neuro , Inc., a Delaware corporation (the “ Company ”), filed a Certificate of Elimination (the “ Certificate of Elimination ”) with the Secretary of State of the State of Delaware with respect to the Company’s Series A convertible preferred stock (the “ Series A Preferred Stock ”), which, effective upon filing, eliminated from the Company’s Certificate of Incorporation, as amended, all matters set forth in the Certificate of Designations for the Series A Preferred Stock.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Alzamend Neuro, Inc. filing history →

Source: SEC EDGAR

accession 0001214659-25-010209

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.